Columbia Laboratories, Inc. (CBRX) Reports In-Line Q3 EPS, Sales Miss Expectations

Columbia Laboratories, Inc. (NASDAQ: CBRX) reported Q3 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $4.95 million versus the consensus estimate of $5.61 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Biogen (BIIB) tops earnings expectations but revenue falls short
• PROG Holdings Inc (PRG) Tops Q1 EPS by 9c
• Hasbro (HAS) brand strength sees earnings top expectations